OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX) in a research note issued to investors on Monday morning. The brokerage issued a sell rating on the stock.

OncoCyte Price Performance

Shares of NASDAQ OCX opened at $2.98 on Monday. The firm has a fifty day moving average of $3.03 and a 200 day moving average of $3.10. OncoCyte has a one year low of $2.08 and a one year high of $7.40.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. AWM Investment Company Inc. lifted its position in OncoCyte by 109.4% in the second quarter. AWM Investment Company Inc. now owns 14,185,664 shares of the company’s stock valued at $3,263,000 after buying an additional 7,412,613 shares during the last quarter. Millennium Management LLC acquired a new position in OncoCyte in the second quarter valued at about $896,000. Goldman Sachs Group Inc. lifted its position in OncoCyte by 5.7% in the first quarter. Goldman Sachs Group Inc. now owns 460,004 shares of the company’s stock valued at $686,000 after buying an additional 24,964 shares during the last quarter. Vanguard Group Inc. lifted its position in OncoCyte by 3.2% in the fourth quarter. Vanguard Group Inc. now owns 247,873 shares of the company’s stock valued at $620,000 after buying an additional 7,784 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in OncoCyte by 23.8% in the second quarter. Geode Capital Management LLC now owns 1,228,553 shares of the company’s stock valued at $283,000 after buying an additional 236,099 shares during the last quarter. Institutional investors and hedge funds own 55.35% of the company’s stock.

About OncoCyte

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.